Yet another interesting, fulfilling, and extraordinary year is coming to an end. 2022 has brought us new challenges and opportunities, gave us a chance to broaden our horizons, and brought us together with new and existing partners.
Each of us at GCT wishes you an enjoyable Holiday Season and a new year filled with peace, prosperity, and happiness. We are thankful for the continued dedication of all our partners to advance clinical research and improve global healthcare. We are looking forward to a wonderful and productive 2023 with you!
From all of us at Global Clinical Trials
Moving forward to the new 2023, we want to share a few highlights of 2022 with you:
Expanding our study portfolio
We continue to enhance our clinical experience in Covid-19 – for instance, GCT was selected for a Phase IIb Covid-19 Vaccine Study in Healthy Volunteers. We are also active in other therapeutic areas, including a project from a long-term client – a Respiratory Pediatric Phase IV Сlinical Trial which includes 15 sites in 3 countries: Romania, Bulgaria, and Poland.
GCT continues to be very active in CNS studies as well – among others, we are providing full-service support for an international phase II Dravet Syndrome clinical trial. The study is to be performed in 40 patients at 25 sites globally.
We are also proud to take part in Oncology studies – GCT was selected to manage Phase I Breast Cancer Study. It makes us proud to know that we are contributing to a clinical trial dedicated to such a common type of cancer and we truly hope we can make a change!
We cannot mention all of them, but of course, we are focusing on other, no less important therapeutic areas. GCT has been managing projects in Rare Diseases, CNS, Infectious Diseases, Respiratory Diseases, and others.
Performing a series of audits
We value the trust of our partners and strive to provide top-notch professional quality assurance services to ensure the highest quality of clinical data. We are grateful to our clients for relying on our services and coming back to us repeatedly.
This year we were trusted with a number of audits, including site audits in Europe, QCO Audit in Georgia, an independent Site Audit for a long-term partner.
Expanding our offices
Due to the continuous growth in operations and the number of employees, GCT-India has moved to a new office in Mumbai. The expansion of the representative office and staff in clinical operations will enable further development of GCT’s activities in the region.
We are also happy welcome the new country manager for operations in Slovakia and the Czech Republic – Monika Sarmirova. With the increasing number of ongoing studies in Slovakia, this next seems like the next necessary step.
Attending Pharma and Biotech events
We are thrilled to say that this year has been filled with exciting events, giving us opportunities for new connections and for strengthening existing partnerships.
To name just a few, GCT was present at the CNS Summit, CPHI, ECNP, CTAD.
Stay tuned and see what 2023 updates we will share!